Sheng-Jiun Wu - Johnson & Johnson | 人才画像

基本信息

Career Trajectory

Bio

Sheng-Jiun Wu currently works at the Janssen Research and Development, LLC, Johnson & Johnson. Sheng-Jiun does research in Biotechnology, Molecular Biology and Structural Biology. Their most recent publication is 'Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality'.

Research Interests

Papers共 61 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

"Stapling" Scfv for Multispecific Biotherapeutics of Superior Properties

Lauren E. Boucher,Elisabeth Geyer Prinslow,Michael Feldkamp,Fang Yi,Rupesh Nanjunda,Sheng-Jiun Wu, Tun Liu,Eilyn R. Lacy,Steven Jacobs,Natalia Kozlyuk, Brian Del Rosario,Bingyuan Wu,Patricia Aquino, Robert C. Davidson, Samantha Heyne, Nicholas Mazzanti, James Testa,Michael D. Diem,Elsa Gorre,Andrew Mahan,Hirsh Nanda,Harsha P. Gunawardena,Alexis Gervais,Anthony A. Armstrong,Alexey Teplyakov,Chichi Huang,Adam Zwolak,Partha Chowdhury, Cheung,Jinquan Luo

MABS（2023）

Cited13Views0WOSBibtex

Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Anna Kuchnio,Danlin Yang,Nele Vloemans, Cassandra Lowenstein,Ivo Cornelissen, Ricardo Amorim, Chao Han,Siddharth Sukumaran,Lut Janssen, Toon Suls,Mariette Bekkers,Elena Lasorsa, Lorena Fontana, Nicole Medeiros,Bingyuan Wu, Jun Chen,Michael Feldkamp,Sheng-Jiun Wu, Habtom Habte, John Krayer, Cam Holland, M. Phillip Deyoung,Yusri A. Elsayed,Ulrike Philippar

Bloodno. Supplement 1 (2022): 3105-3106

Cited8Views0Bibtex

Discovery and Pharmacological Characterization of Cetrelimab (JNJ-63723283), an Anti–programmed Cell Death Protein-1 (PD-1) Antibody, in Human Cancer Models

DeAngelis Nikki,Ferrante Catherine,Powers Gordon,Sendecki Jocelyn,Mattson Bethany,Pizutti Darlene,Packman Kathryn,Wang Weirong,Trouba Kevin,Nanjunda Rupesh,Wheeler John, Brittingham Ray,Wu Sheng-Jiun,Luo Jinquan,Lorenzi Matthew V.,Verona Raluca I.

Cancer Chemotherapy and Pharmacology（2022）

Cited7Views0WOSBibtex

Abstract 5662: JNJ-67571244: A Novel Anti-Cd33 C2 Domain Binding Bispecific Antibody with Potent T Cell Redirection Activity

Priyanka Nair-Gupta, M. Diem, D. Reeves,Weirong Wang, R. Schulingkamp,Katrin Sproesser,Bethany Mattson, B. Heidrich, J. Joseph,J. Sendecki,Brad Foulk, Gerald C. Chu, D. Fink, Q. Jiao,Sheng‐Jiun Wu,K. Packman, Y. Elsayed, R. Attar, F. Gaudet

semanticscholar（2020）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn